



NEWS RELEASE

Revvity Launches Signals LabGistics Solution to Connect and Orchestrate Scientific Workflows

2026-10-20

- AI-first solution bridges workflow coordination gaps and accelerates technology transfer from early discovery through development and manufacturing
- Multi-tier execution, centralized data and real-time monitoring capabilities improve visibility and traceability, designed to adhere to complex regulatory and quality requirements
- Unified laboratory ecosystem drives innovation across pharma, biotech, specialty chemical and materials sciences through coordinated scientific workflows

WALTHAM, Mass.--(BUSINESS WIRE)-- **Revvity, Inc.** (NYSE: RVTY), announced that its **Revvity Signals Software** business is launching the **Signals LabGistics™** solution, an AI-first, scientific workflow orchestration solution designed to connect and coordinate processes, workflows, and tasks from discovery to manufacturing.

The Signals LabGistics offering uses AI-powered workflow design to translate natural-language descriptions and standard operating procedures into coordinated scientific workflows. As pharmaceutical, biotechnology, and specialty chemicals organizations pursue increasingly complex innovations – from novel therapeutics to advanced material formulations – fragmented systems and manual handoffs slow scientific progress, especially during tech transfer from R&D to manufacturing. The Signals LabGistics solution provides an intelligent orchestration layer that helps organizations connect teams, systems and processes to execute workflows more seamlessly. By connecting real-time data and insights in a single digital environment, the solution helps contextualize decision-making and continuously improve scientific processes.

“Scientific innovation is increasingly dependent on the ability to coordinate work across people, systems and stages of development,” said Kevin Willoe, president of Revvity Signals Software. “Our Signals LabGistics offering brings

those moving parts together and helps organizations move promising therapies and new products forward with greater speed, consistency and confidence.”

In addition to operating within the broader Revvity Signals Software ecosystem, the Signals LabGistics solution is designed to work within existing laboratory and manufacturing platforms and extend to adjacent systems over time. This, along with capabilities for multi-tier execution and real-time monitoring, helps improve the flow of information, samples and activities across independent teams. Scientists and managers can then better understand workflow status, identify emerging bottlenecks and respond before delays affect broader development timelines.

The Signals LabGistics solution also offers flexible compliance and quality capabilities tailored to unique industry requirements. These capabilities can support pharmaceutical and biotechnology organizations that need to maintain GxP compliance across connected environments, or specialty chemicals organizations and materials science companies looking to minimize additional regulatory overhead.

The Signals LabGistics solution is expected to be available in the United States, Canada, Europe and Japan in December 2026.

About Revvity

At Revvity, “impossible” is inspiration, and “can’t be done” is a call to action. Revvity provides health science solutions, technologies, expertise, and services that deliver complete workflows from discovery to development, and diagnosis to cure. Revvity is revolutionizing what’s possible in healthcare, with specialized focus areas in translational multi-omics technologies, biomarker identification, imaging, prediction, screening, detection and diagnosis, informatics and more.

With 2025 revenue of \$2.9 billion and approximately 11,000 employees, Revvity serves customers across pharmaceutical and biotech, diagnostic labs, academia and governments. It is part of the S&P 500 index and has customers in more than 160 countries.

Stay updated by following our **Newsroom**, **LinkedIn**, **X**, **YouTube**, **Facebook** and **Instagram**.

Investor Relations

Steve Willoughby

steve.willoughby@revvity.com

Media Relations

Chet Murray

(781) 462-5126

chet.murray@revvity.com

Source: Revvity